MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential

Penticuff, Justin C.; Woolbright, Benjamin L.; Sielecki, Thais M.; Weir, Scott J.; Taylor, John A.

doi:10.1038/s41585-019-0171-9

Cited by 79 publications

(80 citation statements)

References 120 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…MIF may also contribute to immunoinflammatory events during development of Duchenne s syndrome [37] and seems to play a pathogenetic role in major depressive disorders [38]. More recent studies also indicate that MIF is implicated in certain forms of cancer phenotypes such as melanoma, glioblastoma, prostate cancers, and neuroblastoma [39][40][41][42][43][44][45].…”

Section: Biology Physiology and Physiopathology Of Mifmentioning

confidence: 99%

The Role of Macrophage Migration Inhibitory Factor in Alzheimer′s Disease: Conventionally Pathogenetic or Unconventionally Protective?

et al. 2020

View full text Add to dashboard Cite

Recent preclinical and clinical observations have offered relevant insights on the etiopathogenesis of late onset Alzheimer′s disease (AD) and upregulated immunoinflammatory events have been described as underlying mechanisms involved in the development of AD. Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine produced by several cells of the innate and adaptive immune system, as well as non-immune cells. In the present review, we highlight experimental, genetic, and clinical studies on MIF in rodent models of AD and AD patients, and we discuss emerging therapeutic opportunities for tailored modulation of the activity of MIF, that may potentially be applied to AD patients. Dismantling the exact role of MIF and its receptors in AD may offer novel diagnostic and therapeutic opportunities in AD.

show abstract

Section: Biology Physiology and Physiopathology Of Mifmentioning

confidence: 99%

The Role of Macrophage Migration Inhibitory Factor in Alzheimer′s Disease: Conventionally Pathogenetic or Unconventionally Protective?

et al. 2020

View full text Add to dashboard Cite

show abstract

“…We and others have shown that MIF and DDT are involved in several diseases of different origins such as immunoinflammatory and autoimmune diseases, neurodegenerative and neuropsychiatric diseases, and cancer [24][25][26][27][28][29][30][31].…”

Section: Mif and Cancermentioning

confidence: 99%

“…In addition, evidence generated during the last 15 years has also supported a pro-oncogenic role of MIF in certain types of cancers [29][30][31]. MIF may upregulate several tumorigenic processes, including tumor growth, invasiveness, and angiogenesis [32] primarily, but not exclusively, through its angiogenetic action, its AKT mediated antiapoptotic effects, and the inhibition of p53 function.…”

Section: Mif and Cancermentioning

confidence: 99%

“…Numerous preclinical and clinical studies have demonstrated that MIF is overexpressed and may correlate with tumor aggressiveness in many different types of human cancers such as prostate , bladder, and kidney cancer [30], cervical cancer [20], ovarian cancer [44,45], breast cancer [29], gastric cancer [29], hepatocellular carcinoma [46], colon cancer [47,48], pancreatic cancer [49,50], gallbladder cancer [51], lung cancer [29,52], melanoma [31], head and neck cancer [29], acute myeloid leukemia [53,54], glioblastoma [15,55,56], and NB [57][58][59][60]. Moreover, elevated MIF expression is correlated with a worse patient overall survival in a large variety of cancers such as breast cancer [29], gastric cancer [29], hepatocellular carcinoma [61], pancreatic cancer [49,50], metastatic melanoma [31], head and neck cancer [29], esophageal squamous cell carcinoma [62], acute myeloid leukemia [53], glioblastoma [29,56], and NB [57].…”

Section: Mif and Cancermentioning

confidence: 99%

“…Furthermore, the ISO-1 derivative ISO-66 reduced tumor growth in murine models of melanoma and colon cancer [15,74]. The oxazoline derivatives MIF inhibitors CPSI-2705 and CPSI-1306 reduced tumor growth and spreading in mouse models of bladder and skin cancer [30,78,84]. Another effective MIF inhibitor was the isocoumarin compound SCD-19, which reduced tumor growth in a murine model of lung cancer [15,74,76].…”

Section: Chemotherapeutic Action Of Mif And/or Ddt Inhibitors In Precmentioning

confidence: 99%

See 2 more Smart Citations

Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?

et al. 2020

View full text Add to dashboard Cite

Neuroblastoma (NB) is the most frequent extracranial pediatric tumor. Despite the current available multiple therapeutic options, the prognosis for high-risk NB patients remains unsatisfactory and makes the disease a clear unmet medical need. Thus, more tailored therapeutic approaches are warranted to improve both the quality of life and the survival of the patients. Macrophage migration inhibitory factor (MIF) is a pleiotropic cytokine that plays a key role in several diseases, including cancer. Preclinical and clinical studies in NB patients convergently indicate that MIF exerts pro-tumorigenic properties in NB. MIF is upregulated in NB tumor tissues and cell lines and it contributes to NB aggressiveness and immune-escape. To date, there are only a few data about the role of the second member of the MIF family, the MIF homolog d-dopachrome tautomerase (DDT), in NB. Here, we review the preclinical and clinical studies on the role of the MIF family of cytokines in NB and suggest that MIF and possibly DDT inhibitors may be promising novel prognostic and therapeutic targets in NB management.

show abstract

Macrophage migration inhibitory factor (MIF) predicts survival in patients with clear cell renal cell carcinoma

Parol‐Kulczyk,

Durślewicz,

Blonkowska

et al. 2024

The Journal of Pathology CR

View full text Add to dashboard Cite

Clear cell renal cell carcinoma (ccRCC) is one of the most common subtypes of renal cancer, with 30% of patients presenting with systemic disease at diagnosis. This aggressiveness is a consequence of the activation of epithelial–mesenchymal transition (EMT) caused by many different inducers or regulators, signaling cascades, epigenetic regulation, and the tumor environment. Alterations in EMT‐related genes and transcription factors are associated with poor prognosis in ccRCC. EMT‐related factors suppress E‐cadherin expression and are associated with tumor progression, local invasion, and metastasis. The aim of this study was to investigate the expression levels and prognostic significance of macrophage migration inhibitory factor (MIF), β‐catenin, and E‐cadherin in ccRCC patients. We examined these proteins immunohistochemically in tumor areas and adjacent normal tissues resected from patients with ccRCC. Analysis of the cancer genome atlas (TCGA) cohort was performed to verify our results. Kaplan–Meier analysis showed that median overall survival (OS) was significantly shorter in patients with tumors exhibiting high MIFn and MIFm‐c levels compared to those with low MIFn and MIFm‐c levels (p = 0.03 and p = 0.007, respectively). In the TCGA cohort, there was a significant correlation between MIF expression and OS (p < 0.0001). In conclusion, this study provides further evidence for the biological and prognostic value of MIF in the context of EMT as a potential early prognostic marker for advanced‐stage ccRCC.

show abstract

MIF family proteins in genitourinary cancer: tumorigenic roles and therapeutic potential

Cited by 79 publications

References 120 publications

The Role of Macrophage Migration Inhibitory Factor in Alzheimer′s Disease: Conventionally Pathogenetic or Unconventionally Protective?

The Role of Macrophage Migration Inhibitory Factor in Alzheimer′s Disease: Conventionally Pathogenetic or Unconventionally Protective?

Emerging Role of the Macrophage Migration Inhibitory Factor Family of Cytokines in Neuroblastoma. Pathogenic Effectors and Novel Therapeutic Targets?

Macrophage migration inhibitory factor (MIF) predicts survival in patients with clear cell renal cell carcinoma

Contact Info

Product

Resources

About